Early-Stage HER2-Positive Breast Cancer Systemic Therapy

Authored by Samantha El Warrak, published on 2026-09-03 00:56:50.0

The algorithm appropriately recognizes paclitaxel-trastuzumab for selected small node-negative tumors and approximately 1 year of HER2-directed therapy. However, the stage II-III pathway omits the current preferred neoadjuvant approach, surgery-based response assessment, and adjuvant trastuzumab emtansine for residual invasive disease. Its stage groupings also oversimplify T1 tumors, particularly T1cN0 and very small T1a lesions.

  1. Newly Diagnosed Early HER2+ Breast Cancer
    A contemporary early-breast-cancer guideline supports the overall diagnostic, staging, and systemic-treatment framework for nonmetastatic HER2-positive disease.
    • Assess Stage & Pathology
      • Stage I, cN0 (T1a–c)
        Guidelines support risk-adapted management of small node-negative tumors, but T1a and T1b should be distinguished. Systemic therapy for T1aN0 disease is individualized, while trastuzumab-based therapy is more commonly recommended for T1b and larger tumors.
        • Surgery
          • Adjuvant Paclitaxel + Trastuzumab (TH)
            The APT regimen is a widely accepted de-escalated option for selected node-negative HER2-positive tumors, with excellent long-term outcomes. Evidence comes from a prospective single-arm phase II study rather than a randomized comparison.
            • Complete ~1 Year of HER2-Directed Therapy
              • Follow-Up & Surveillance
                Clinical exam, imaging as indicated
      • Stage II–III (≥T1c Or Node Positive)
        • Neoadjuvant T-DXd ×4 → THP ×4 OR TCHP / Anthracycline-Taxane + HP
          Chemotherapy plus HER2-directed therapy is standard, and adjuvant pertuzumab benefit is concentrated in node-positive disease. This node is incomplete because stage II-III disease is generally treated neoadjuvantly, with postoperative therapy determined by pathologic response.
          • Surgery
            • Pathologic Response?
              • pCR
                • Continue Trastuzumab ± Pertuzumab to Complete ~1 Year of HER2-Directed Therapy
                  • Follow-Up & Surveillance
                    Clinical exam, imaging as indicated
              • Residual invasive disease
                • Adjuvant T-DXd
                  • Follow-Up & Surveillance
                    Clinical exam, imaging as indicated
  2. If HR+: initiate appropriate adjuvant endocrine therapy
tosprivacy